Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

BACKGROUND: Bisphosphonates might modulate the development of symptomatic bone metastases in men with prostate cancer. The Medical Research Council (MRC) PR05 and PR04 randomised controlled trials assessed the use of sodium clodronate, an oral, first-generation bisphosphonate. We report the final an...

Descripción completa

Detalles Bibliográficos
Autores principales: Dearnaley, David P, Mason, Malcolm D, Parmar, Mahesh KB, Sanders, Karen, Sydes, Matthew R
Formato: Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2009
Materias:
Fast track — Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748902/
https://www.ncbi.nlm.nih.gov/pubmed/19674936
http://dx.doi.org/10.1016/S1470-2045(09)70201-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748902/
https://www.ncbi.nlm.nih.gov/pubmed/19674936
http://dx.doi.org/10.1016/S1470-2045(09)70201-3

Ejemplares similares